Louise-Granofsky Psychosocial Oncology Program, Segal Cancer Centre, and Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC.
Psychology Department, McGill University, and Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC.
Curr Oncol. 2014 Feb;21(1):e89-95. doi: 10.3747/co.21.1741.
Pain and anxiety have been reported as primary concerns for patients with head-and-neck, gynecologic, and prostate cancers undergoing high dose rate (hdr) brachytherapy. However, almost no research has been published on the degree to which these symptoms are experienced by rectal cancer patients undergoing hdr brachytherapy. We conducted a pilot study examining the experiences of rectal cancer patients during hdr brachytherapy, specifically the intensity and trajectory of their anxiety and pain.
Rectal cancer patients (n = 25) who received hdr brachytherapy treatment at a hospital in Montreal, Quebec, completed verbal analog scales for pain and anxiety at 4 time points over 4 treatment days.
On all 4 days, a subset of patients reported moderate-to-severe anxiety before applicator insertion. Pain increased significantly from the time patients were lying on the table to immediately after insertion of the applicator (p < 0.001). Insertion of the applicator appears to be the most painful part of the procedure, and although anxiety declined to below baseline after applicator removal, pain remained somewhat elevated. Some patients required conscious sedation; however, reports of moderate-to-severe pain were more frequent from patients who received pain medications than from patients who did not receive such medication (p < 0.05).
Most patients with rectal cancer tolerated hdr rectal brachytherapy well, although the procedure is stressful and painful for some. Insertion of the applicator was found to be the point of maximal pain, and medication was not always completely successful at alleviating the pain, suggesting that additional psychosocial interventions might be needed, with particular emphasis on the time of applicator insertion.
接受高剂量率(HDR)近距离放射治疗的头颈部、妇科和前列腺癌患者主要关注疼痛和焦虑。然而,几乎没有研究发表过关于接受 HDR 近距离放射治疗的直肠癌患者经历这些症状的程度。我们进行了一项试点研究,调查了直肠癌患者在 HDR 近距离放射治疗过程中的体验,特别是他们焦虑和疼痛的强度和轨迹。
在魁北克省蒙特利尔的一家医院接受 HDR 近距离放射治疗的直肠癌患者(n=25)在 4 个治疗日的 4 个时间点完成了疼痛和焦虑的口头模拟量表。
在所有 4 天,一部分患者在插入施源器前报告有中重度焦虑。从患者躺在治疗台上到插入施源器后立即,疼痛显著增加(p<0.001)。插入施源器似乎是该过程中最痛苦的部分,尽管在施源器移除后焦虑下降到基线以下,但疼痛仍有些升高。一些患者需要进行清醒镇静;然而,接受疼痛药物治疗的患者比未接受此类药物治疗的患者报告中度至重度疼痛的频率更高(p<0.05)。
大多数直肠癌患者能很好地耐受 HDR 直肠近距离放射治疗,但对一些患者来说,该过程是有压力和痛苦的。插入施源器是疼痛最剧烈的部位,药物并不能完全缓解疼痛,这表明可能需要额外的社会心理干预,特别强调施源器插入的时间。